Peginterferon beta-1a API is a specialized PEGylated recombinant interferon beta-1a used in pharmaceutical and biopharmaceutical development. It is a long-acting form of recombinant human interferon beta-1a in which a single linear polyethylene glycol (PEG) chain is covalently attached to the N-terminal amino acid of the interferon protein.
With an approximate molecular mass of 44 ± 2 kDa, Peginterferon beta-1a combines a recombinant glycoprotein component with a 20 kDa PEG moiety. The protein consists of 166 amino acids and is produced using recombinant technology in Chinese hamster ovary (CHO) cells.
Peginterferon beta-1a is a complex biological molecule and requires specialized manufacturing and analytical controls. Unlike conventional chemical APIs, its quality cannot be adequately described using only routine HPLC assay, melting point, residue on ignition, and similar small-molecule tests.
The molecule is characterized using a combination of physicochemical and biological analytical procedures. These may include peptide mapping, chromatographic purity testing, mass spectrometry, molecular-weight characterization, glycosylation analysis, aggregate determination and biological activity assays.
The CAS number of Peginterferon beta-1a is 1211327-92-2. FDA substance information identifies the molecule with an average molecular weight of approximately 44,000 Da, while regulatory characterization provides the more specific molecular-mass range of approximately 44 ± 2 kDa.
Peginterferon beta-1a consists of recombinant human interferon beta-1a modified through site-specific PEGylation. The interferon beta-1a protein is a glycosylated recombinant protein containing 166 amino acids.
A single linear 20 kDa methoxy polyethylene glycol (mPEG) chain is attached to the N-terminal amino group of the protein. This PEGylation changes the molecular properties and pharmacokinetic behavior of the interferon molecule.
The combination of recombinant protein, glycosylation and PEG modification makes Peginterferon beta-1a a structurally complex biological substance requiring product-specific characterization.
The manufacture of Peginterferon beta-1a involves recombinant production of interferon beta-1a followed by purification and controlled PEGylation. The recombinant protein is produced using genetically engineered CHO cells.
Following protein production, purification processes are used to remove process-related impurities and obtain the required interferon beta-1a quality. PEGylation is subsequently performed using an activated 20 kDa PEG reagent, followed by purification and characterization of the PEGylated protein.
Important manufacturing controls include:
For pharmaceutical applications, these attributes should be controlled through validated, product-specific analytical procedures.
Peginterferon beta-1a is associated with the treatment of relapsing forms of multiple sclerosis. The molecule belongs to the interferon beta therapeutic class and is associated with the pharmaceutical product PLEGRIDY.
Interferon beta products exert their biological effects through interaction with cellular interferon receptors and modulation of immune and inflammatory pathways. Pegylation allows the active interferon protein to have a longer pharmacokinetic profile than non-PEGylated interferon beta formulations.
A reliable Peginterferon beta-1a API supplier in India should have appropriate capabilities for handling complex recombinant proteins and PEGylated biological substances. Pharmaceutical buyers should evaluate the supplier's quality systems, analytical capabilities, documentation and batch-to-batch consistency.
Important documentation may include:
Quality control for Peginterferon beta-1a requires an orthogonal analytical strategy. A single chromatographic assay cannot adequately establish the identity, purity and biological integrity of a PEGylated recombinant glycoprotein.
Analytical characterization can include RP-HPLC, SEC-HPLC, peptide mapping, mass spectrometry and biological potency testing, together with suitable methods for assessing aggregates, degradation and molecular variants.
Because public regulatory documents do not establish universal numerical limits for every API CMS field, values such as assay percentage, individual impurity, total impurity and water content should be taken from the applicable validated product specification rather than copied from unrelated small-molecule APIs.
Peginterferon beta-1a represents an advanced PEGylated recombinant protein platform combining biotechnology and polymer conjugation. Its approximately 44 kDa molecular mass and site-specific 20 kDa PEG modification distinguish it from conventional interferon beta products.
For pharmaceutical development, sourcing should focus on:
Appropriate pharmaceutical documentation
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.5% |